BioSpring and Pantherna Agree on Strategic Cooperation in the Field of Genome Editing

BioSpring GmbH and Pantherna Therapeutics GmbH, have agreed on a strategic collaboration in the field of research and development and signed a cooperation agreement mid-July.

The focus of the collaboration targets further development and licensing of therapeutic mRNA molecules based on PTXmRNA® technology specifically for genome editing applications. BioSpring is the world's leading provider of RNA for genome editing applications. Pantherna specializes in the development of novel lipid nanoparticle (LNP) formulations (PTXDLNP® technology) for the organ- and cell-selective uptake of therapeutically active mRNA (PTXmRNA®) for the effective expression of proteins in various diseases.

"With this research collaboration, we are combining the outstanding expertise of our companies in the field of therapeutic mRNA, creating synergies and thus developing the potential for innovative solutions for our clients," stated Dr Hüseyin Aygün, Chief Scientific Officer (CSO) and co-owner of BioSpring GmbH.

Dr Jörg Kaufmann, CSO of Pantherna Therapeutics GmbH, adds:  "We are pleased to support Biospring and its customers seeking solutions for customized mRNA constructs and nucleic acid delivery systems in the field of genome editing with our mRNA-LNP expertise."

BioSpring and Pantherna have previously collaborated on joint projects. With this new collaboration, the companies are placing particular emphasis on utilizing mRNA technology within the rapidly expanding field of genome editing. The targeted modification of genes (or genome editing) holds the promise of effectively treating diseases or even completely curing them. In addition to rare diseases that have genetic causes, these can also include common diseases such as cardiovascular diseases, or cancer. The parties have agreed not to disclose the financial details of the collaboration.